Related Experiment Video
Updated: Nov 30, 2025
02:32
Author Spotlight: Novel Intraperitoneal Injection Method for Zebrafish Cardiotoxicity Models
Published on: March 29, 2024
2.5K
Adriamycin does not damage podocytes of zebrafish larvae
Maximilian Schindler1, Antje Blumenthal1, Marcus Johannes Moeller2
1Department of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany.
Plos One
|November 13, 2020
Summary
Adriamycin does not induce kidney damage in zebrafish larvae, hindering efforts to screen for focal segmental glomerulosclerosis (FSGS) drugs. Further research is needed to establish a reliable FSGS model in zebrafish for drug discovery.
Area of Science:
- Nephrology
- Developmental Biology
- Toxicology
Background:
- Podocytes are crucial for kidney filtration; injury leads to diseases like focal segmental glomerulosclerosis (FSGS).
- Effective treatments for FSGS are lacking, necessitating drug screening.
- Zebrafish larvae offer a promising model for kidney research due to their homology and rapid development.
Purpose of the Study:
- To establish a zebrafish model for inducing FSGS-like kidney injury using adriamycin.
- To evaluate adriamycin's efficacy in causing podocyte damage and glomerular dysfunction in zebrafish larvae.
Main Methods:
- Zebrafish larvae were exposed to varying concentrations of adriamycin.
- Kidney integrity was assessed using histology, filtration assays, 2-photon microscopy, RT-(q)PCR, and transmission electron microscopy.
Main Results:
- Adriamycin treatment did not cause glomerular injury or filtration barrier defects in zebrafish larvae.
- Histological and imaging analyses confirmed intact podocytes and filtration barriers post-treatment.
Conclusions:
- Adriamycin is ineffective in inducing podocyte damage or FSGS-like phenotypes in zebrafish larvae.
- Developing a reliable method to induce FSGS in zebrafish is essential for future drug screening and discovery.
